S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Arcadia Biosciences Stock Forecast, Price & News

-0.09 (-7.56%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
529,540 shs
Average Volume
1.24 million shs
Market Capitalization
$24.40 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RKDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Arcadia Biosciences logo

About Arcadia Biosciences

Arcadia Biosciences, Inc. is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. The company's portfolio of agricultural productivity traits includes Nitrogen Use Efficiency, Water Use Efficiency, Drought Tolerance, Salinity Tolerance and Herbicide Tolerance. It has presence in the United States, Africa, India, the United Arab Emirates, Belgium, France and Canada. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.


Arcadia Biosciences (NASDAQ:RKDA) Issues Quarterly Earnings Results
November 16, 2021 |  americanbankingnews.com
Arcadia Biosciences Earnings Preview
November 14, 2021 |  benzinga.com
Arcadia Biosciences Announces Leadership Transition
September 7, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Agricultural production - crops
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$8.03 million
Book Value
$1.34 per share


Net Income
$-4.66 million
Pretax Margin




Free Float
Market Cap
$24.40 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.11 out of 5 stars

Basic Materials Sector

114th out of 223 stocks

Agricultural Production - Crops Industry

5th out of 16 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

Is Arcadia Biosciences a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcadia Biosciences stock.
View analyst ratings for Arcadia Biosciences
or view top-rated stocks.

How has Arcadia Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RKDA shares have decreased by 65.3% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Arcadia Biosciences

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its quarterly earnings results on Monday, November, 15th. The basic materials company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.13. Arcadia Biosciences had a negative trailing twelve-month return on equity of 44.75% and a net margin of 3.98%. During the same quarter in the previous year, the firm earned ($0.54) earnings per share.
View Arcadia Biosciences' earnings history

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Arcadia Biosciences shares reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for RKDA?

2 equities research analysts have issued 1-year price targets for Arcadia Biosciences' shares. Their forecasts range from $4.50 to $7.00. On average, they expect Arcadia Biosciences' stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 422.7% from the stock's current price.
View analysts' price targets for Arcadia Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the following people:
  • Matthew T. Plavan, President, Chief Executive Officer & Director
  • Belinda Yao, Vice President-Operations
  • Pamela Haley, Chief Financial Officer
  • Randy Shultz, Chief Technology Officer
  • Chris Cuvelier, Chief Growth Officer

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences CEO Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among Arcadia Biosciences' employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include MYDA Advisors LLC (0.27%), Citadel Advisors LLC (0.00%) and HAP Trading LLC (0.00%).
View institutional ownership trends for Arcadia Biosciences

Which institutional investors are selling Arcadia Biosciences stock?

RKDA stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, and HAP Trading LLC.
View insider buying and selling activity for Arcadia Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Arcadia Biosciences stock?

RKDA stock was purchased by a variety of institutional investors in the last quarter, including MYDA Advisors LLC.
View insider buying and selling activity for Arcadia Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $1.10.

How much money does Arcadia Biosciences make?

Arcadia Biosciences has a market capitalization of $24.40 million and generates $8.03 million in revenue each year. The basic materials company earns $-4.66 million in net income (profit) each year or $0.17 on an earnings per share basis.

How many employees does Arcadia Biosciences have?

Arcadia Biosciences employs 58 workers across the globe.

What is Arcadia Biosciences' official website?

The official website for Arcadia Biosciences is www.arcadiabio.com.

Where are Arcadia Biosciences' headquarters?

Arcadia Biosciences is headquartered at 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at (530) 756-7077, via email at [email protected], or via fax at 530-756-7027.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.